488 related articles for article (PubMed ID: 11779082)
1. Angiogenesis inhibition in solid tumors.
Rosen LS
Cancer J; 2001; 7 Suppl 3():S120-8. PubMed ID: 11779082
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
3. Role of angiogenesis inhibitors in acute myeloid leukemia.
Fiedler W; Staib P; Kuse R; Dührsen U; Flasshove M; Cavalli F; Hossfeld DK; Berdel WE
Cancer J; 2001; 7 Suppl 3():S129-33. PubMed ID: 11779083
[TBL] [Abstract][Full Text] [Related]
4. SU6668, a multitargeted angiogenesis inhibitor.
Hoekman K
Cancer J; 2001; 7 Suppl 3():S134-8. PubMed ID: 11779084
[TBL] [Abstract][Full Text] [Related]
5. Endothelial survival factors as targets for antineoplastic therapy.
Reinmuth N; Stoeltzing O; Liu W; Ahmad SA; Jung YD; Fan F; Parikh A; Ellis LM
Cancer J; 2001; 7 Suppl 3():S109-19. PubMed ID: 11779081
[TBL] [Abstract][Full Text] [Related]
6. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas.
Angelov L; Salhia B; Roncari L; McMahon G; Guha A
Cancer Res; 1999 Nov; 59(21):5536-41. PubMed ID: 10554031
[TBL] [Abstract][Full Text] [Related]
8. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
Stopeck A; Sheldon M; Vahedian M; Cropp G; Gosalia R; Hannah A
Clin Cancer Res; 2002 Sep; 8(9):2798-805. PubMed ID: 12231519
[TBL] [Abstract][Full Text] [Related]
9. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
10. Advances in the use of angiogenesis inhibitors in cancer.
Pinedo HM
Cancer J; 2001; 7 Suppl 3():S107-8. PubMed ID: 11779080
[No Abstract] [Full Text] [Related]
11. Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells.
Bischof M; Abdollahi A; Gong P; Stoffregen C; Lipson KE; Debus JU; Weber KJ; Huber PE
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1220-32. PubMed ID: 15519795
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats.
Roman CD; Choy H; Nanney L; Riordan C; Parman K; Johnson D; Beauchamp RD
J Surg Res; 2002 Jun; 105(1):43-7. PubMed ID: 12069500
[TBL] [Abstract][Full Text] [Related]
13. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.
Mendel DB; Laird AD; Smolich BD; Blake RA; Liang C; Hannah AL; Shaheen RM; Ellis LM; Weitman S; Shawver LK; Cherrington JM
Anticancer Drug Des; 2000 Feb; 15(1):29-41. PubMed ID: 10888034
[TBL] [Abstract][Full Text] [Related]
14. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM
Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
Giles FJ; Cooper MA; Silverman L; Karp JE; Lancet JE; Zangari M; Shami PJ; Khan KD; Hannah AL; Cherrington JM; Thomas DA; Garcia-Manero G; Albitar M; Kantarjian HM; Stopeck AT
Cancer; 2003 Apr; 97(8):1920-8. PubMed ID: 12673719
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis inhibitors in the treatment of lung cancer.
Sun S; Schiller JH
Crit Rev Oncol Hematol; 2007 May; 62(2):93-104. PubMed ID: 17306557
[TBL] [Abstract][Full Text] [Related]
18. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Langer CJ; Natale RB
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
Tandle A; Libutti SK
Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
[TBL] [Abstract][Full Text] [Related]
20. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.
Polverino A; Coxon A; Starnes C; Diaz Z; DeMelfi T; Wang L; Bready J; Estrada J; Cattley R; Kaufman S; Chen D; Gan Y; Kumar G; Meyer J; Neervannan S; Alva G; Talvenheimo J; Montestruque S; Tasker A; Patel V; Radinsky R; Kendall R
Cancer Res; 2006 Sep; 66(17):8715-21. PubMed ID: 16951187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
